Comparison · NCT02963922-sae
Liraglutide 3.0 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Liraglutide 3.0 mg vs Placebo: serious adverse events. Trial comparisons, record NCT02963922-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02963922-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0821 | 0.0511 | 0.129 | wilson | |
| Risk in group 2 | 0.0964 | 0.0626 | 0.146 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0144 | -0.0726 | 0.0436 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.851 | 0.451 | 1.61 | log | |
| Odds ratio, group 1 over group 2 | 0.837 | 0.417 | 1.68 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Liraglutide 3.0 mg than on Placebo | 69.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Liraglutide 3.0 mg | Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks. | 16 | 195 | EG000 |
| Group 2 | Placebo | Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks. | 19 | 197 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From the date of first dose of trial product (week 0) to end of treatment (week 56) + post treatment follow-up of 30 days.
Source ClinicalTrials.gov
Trial
- Title
- Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
- NCT number
- NCT02963922
- Phases
- PHASE3
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- Liraglutide 3.0 mg, Placebo
- Lead sponsor
- Novo Nordisk A/S
- Results first posted
- 2019-11-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02963922?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02963922-sae